What Does the Historical and Current Cardiac Marker Market Size Trend Indicate?
The cardiac marker market has seen considerable growth due to a variety of factors.
•The market size of cardiac markers has seen a quick expansion in the past few years. The market is expected to rise from $11.26 billion in 2024 to $12.47 billion in 2025, registering a compound annual growth rate (CAGR) of 10.8%.
The historic increase is associated with factors like a rise in the occurrence of cardiovascular sicknesses, an aging populace and cardiovascular risk, health consciousness initiatives and health check-ups, incorporation of biomarkers in clinical application, and strict regulatory norms and guidelines.
How Will the Cardiac Marker Market Size Evolve over the Forecast Period?
The cardiac marker market is expected to maintain its strong growth trajectory in upcoming years.
• The size of the cardiac marker market is projected to experience a rapid escalation in the coming years, reaching "$20.35 billion by 2029 at a compound annual growth rate (CAGR) of 13.0%.
This anticipated growth within the forecast period can be accredited to the escalating burden of lifestyle-related illnesses, adoption of remote monitoring and telemedicine, customization in medicine and precision diagnostics, incorporation of point-of-care testing (POCT), and the rise in collaborations and partnerships within the healthcare sector. The forecast period is likely to witness significant trends such as the discovery and validation of biomarkers, advancements in personalized medicine approaches, technological breakout in assay platforms, the increased acceptance of high-sensitivity troponin tests, and the growing prevalence of cardiovascular diseases.
What Are The Core Factors Supporting Growth In The Cardiac Marker Market?
The cardiac marker market is poised for growth, driven by the increasing incidence of heart diseases. Cardiac diseases, comprising several conditions impacting heart function or structure leading to myriad health issues, are on a steady rise. These diseases boost the requirement for cardiac markers, used to diagnose and supervise cardiac ailments such as heart attacks, angina, heart failure, and other cardiovascular diseases. Consequently, the need for diagnostic tests or cardiac markers escalates. Data from the British Heart Foundation, a cardiovascular research charity in the UK, indicates an upsurge in coronary heart disease deaths in England. From the onset of the pandemic till August 2022, an additional 30,000 deaths were reported. By August 2022, a record 346,000 individuals were awaiting cardiac treatment. Hence, the cardiac marker market is set to grow, owing to the escalating occurrence of heart diseases.
What Are The Major Segments Within The Global Cardiac Marker Market?
The cardiac marker market covered in this report is segmented –
1) By Biomarker: Troponin, Creatine Kinase-MB (CK-MB), B-type Natriuretic Peptide (BNP), Myoglobin, Other Biomarkers
2) By Product: Reagent, Instrument, Chemiluminescence, Immunofluorescence, Immunochromatography, ELISA
3) By Indication: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Other Indications
4) By End User: Laboratory Testing Facilities, Hospital Labs, Reference Labs, Contract Testing Labs, Point-Of-Care Testing Facilities, Academic Institutions
Subsegments:
1) By Troponin: Troponin I, Troponin T, Troponin Diagnostic Kits
2) By Creatine Kinase-MB (CK-MB): CK-MB Test Kits, CK-MB Diagnostic Panels
3) By B-Type Natriuretic Peptide (BNP): BNP Test Kits, NT-ProBNP Test Kits, BNP Diagnostic Panels
4) By Myoglobin: Myoglobin Test Kits, Myoglobin Diagnostic Panels
5) By Other Biomarkers: Ischemia Modified Albumin (IMA), Heart Fatty Acid Binding Protein (HFABP), C-Reactive Protein (CRP)
Pre-Book The Cardiac Marker Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The Cardiac Marker Market?
The trend of product innovation is increasingly gaining traction in the cardiac marker market. The main competitors in the market are orienting their efforts towards the development of inventive solutions to solidify their standing. For example, in September 2022, MiRxes, a biotech firm from Singapore, confirmed the reliability of a diagnostic test based on microRNA for early identification and diagnosis of diseases. Once the product hits the market, it will augment MiRxes' assortment of blood tests for cancer, providing a comprehensive set of early detection methodologies. This will help mitigate the rising clinical and socioeconomic impacts of severe health conditions, including cancer and cardio-pulmonary diseases.
Who Are the Key Players in the Cardiac Marker Market?
Major companies operating in the cardiac marker market include:
• Abbott Laboratories Inc.
• Siemens AG
• Danaher Corporation
• BioMérieux SA
• F. Hoffmann-La Roche AG
• Beckman Coulter Inc.
• Bio-Rad Laboratories Inc.
• Thermo Fisher Scientific Inc.
• Guangzhou Wondifo Biotech Co. Ltd.
• Creative Diagnostics
• PerkinElmer Inc.
• Tosoh Corporation
• Quidel Corporation
• Randox Laboratories Ltd.
• Getinge Group
• LSI Medience Corporation
• Ortho Clinical Diagnostics
• DiaSorin
• 3M Company
• Atom Medical Corporation
• Bionet America Inc.
• Bistos Inc.
• CareFusion Corporation
• Clinical Innovations LLC
• Abcam plc
• General Electric Company
What Is The Most Dominant Region In The Cardiac Marker Market?
North America was the largest region in the cardiac marker market in 2024. The regions covered in the cardiac marker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
